What is Sevmia?
Sevmia is Apotex's generic of Wegovy (semaglutide), approved by Health Canada on 29 June 2026 for weight management. It comes only as a pen giving 1 mg weekly doses, so it can't cover Wegovy's other dose steps. As of 12 October 2026, Health Canada's database lists it as approved but not yet on sale.
- Every GLP‑1 medicine is a prescription drug in Canada. A doctor, nurse practitioner or other authorized prescriber must assess you first.1
- Prices here are official list or formulary prices, with the date we checked them. We never quote a pharmacy's, clinic's or savings card's price, and we don't name or rank sellers.
- Canadian law bans advertising a drug to the public as a treatment for obesity or diabetes. This page is information, not an ad, and nothing here is for sale. The risks are in Guide 5: Side effects and risks.
What is Sevmia approved for?
Sevmia has Wegovy's approvals: weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition, and in some teenagers.2
Like Wegovy, it is also approved to lower the risk of a non-fatal heart attack in adults with established heart disease and a BMI of 27 or more.2 The Ozempic generics, by contrast, are approved only for type 2 diabetes.3 Sevmia must not be combined with any other semaglutide product.2 Like the other generics, it is "produced by solid-phase synthetic chemistry", while Wegovy is made in yeast.2,4 For teenagers aged 12 to 17, the label needs a BMI at or above the 95th percentile for age and sex and a weight above 60 kg (132 lb).2
Why does the 1 mg-only pen matter?
Because Sevmia's monograph says it "can be prescribed only for 1 mg once weekly dosing", and other products are needed for every other dose.2
Wegovy starts at 0.25 mg and steps up every 4 weeks, through 0.5, 1 and 1.7 mg, to 2.4 mg.2 Each Sevmia pen holds 4 mg, which is 4 weekly 1 mg doses.2 So on its own, Sevmia covers one step of that schedule. Your prescriber decides your dose; the medicines are compared in Guide 6.
When will Sevmia be available, and what will it cost?
We don't know yet: Health Canada's database still showed Sevmia as "Approved", not marketed, on 12 October 2026.1
Ontario's formulary lists a Sevmia pen at $325.05, as "off-formulary", so it isn't a plan benefit there.5 No province covers any weight-management GLP‑1, as Is Wegovy covered in Canada? explains. We'll update this page when Sevmia goes on sale. For the Ozempic generics already sold, see Is there a generic Ozempic in Canada?
- Stomach effects are very common. In the weight trials on the Canadian Wegovy monograph, 44 in 100 people on Wegovy felt sick (nausea), against 16 in 100 on placebo.4
- Gallstones were reported in 1.6 in 100 people on Wegovy and 0.7 in 100 on placebo. Losing weight fast raises the risk.4
- Inflamed pancreas (pancreatitis) was confirmed in 4 people on Wegovy in the weight trials, about 0.2 cases per 100 patient-years, against 1 on placebo.4
- Who shouldn't take it. Not for anyone with a personal or family history of medullary thyroid cancer or MEN 2. Stop it at least 2 months before a planned pregnancy.4
Read the full picture
Related questions
Sources
- Health Canada. Drug Product Database: product records and marketing status for semaglutide and tirzepatide products (for example Ozempic DIN 02471469 "Marketed"; Sevmia DIN 02569582 "Approved", not marketed; Zepbound first marketed 9 July 2025). Searched 12 Oct 2026. health-products.canada.ca
- Apotex. Sevmia (semaglutide injection) Product Monograph, authorized 29 Jun 2026 ("Multi-use pre-filled pen delivering doses of 1 mg, 4 mg / pen"; "SEVMIA can be prescribed only for 1 mg once weekly dosing. Alternative products are needed to achieve doses of Semaglutide Injection exclusive of the 1 mg dose"; Wegovy's weight-management and heart-attack-risk indications; not to be combined with other semaglutide products). pdf.hres.ca (PDF)
- Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. News release, 28 Apr 2026 (Dr. Reddy's, "a generic version of the brand name drug Ozempic", for adults with type 2 diabetes; generics are "pharmaceutically equivalent to the brand name biologic drug"; "many generic medication are 45 to 90% cheaper"). canada.ca
- Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, revised 2 Oct 2026 (indications: adults with BMI 30 or more, or 27 or more with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia or obstructive sleep apnea; ages 12 to under 18 at the 95th percentile and above 60 kg (132 lb); non-fatal heart attack risk with established cardiovascular disease and BMI 27 or more; MASH under the NOC/c policy; nausea 44% vs 16% on placebo; gallstones 1.6% vs 0.7%; stop at least 2 months before a planned pregnancy; do not freeze). pdf.hres.ca (PDF)
- Ontario Ministry of Health. Ontario Drug Benefit Formulary: semaglutide pens (Ozempic $227.94 a pen with the plan paying $78.141; generic semaglutide $78.141 a pen, interchangeable, Limited Use; Sevmia $325.048 a pen, off-formulary interchangeable); tirzepatide not listed. Checked 12 Oct 2026. formulary.health.gov.on.ca
Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on 12 Oct 2026. Prices are official list or formulary prices, never a seller's, savings-card or coupon price, and we don't name or rank sellers. Availability, coverage and recall facts are dated because they change. Figures marked as our arithmetic are worked out from those sources. It's general information, not medical advice, and not an advertisement for any medicine. Talk to a doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. How we write